Atopic Dermatitis

At RAD 2025, Eli Lilly revealed promising results for lebrikizumab in treating atopic dermatitis in patients with skin of color.

At the 2025 Revolutionizing Atopic Dermatitis Conference, Leon Kircik, MD, highlighted the safety of JAK inhibitors, clarified misconceptions around boxed warnings, and discussed the clinical relevance of recent label updates for abrocitinib.

Data presented at the 2025 RAD Conference shows dupilumab improves daily functioning, mental health, and social aspects in patients with atopic dermatitis.

Catch up on coverage from the first day of the 2025 Revolutionizing Atopic Dermatitis Conference held in Nashville, Tennessee.

At RAD 2025, Mona Shahriari, MD, emphasized the cumulative life course impairment of AD in pediatric and adult patients, highlighting its impact on sleep, mental health, family well-being, and quality of life.

Discover groundbreaking insights from the RAD 2025 conference on roflumilast's potential to transform treatment for infant atopic dermatitis.

A poster at RAD 2025 detailed the patient-reported outcomes across skin types and racial groups.

Arcutis Biotherapeutics showcases promising long-term results of Zoryve for atopic dermatitis in young children at RAD 2025, emphasizing safety and efficacy.

Discover the latest breakthroughs in atopic dermatitis treatment and expert insights from the RAD dermatology conference in Nashville.

Catch up on what to expect at this year's RAD conference in Nashville, Tennessee.

Jonathan Silverberg, MD, PhD, MPH, shares his insights on treating and managing CHE.

Through a comprehensive review and meta-analysis, researchers identified the correlation between atopic dermatitis and dementia.

Jonathan Silverberg, MD, PhD, MPH, talks about when and how to take itch into consideration when choosing a therapy for AD.

Jonathan Silverberg, MD, PhD, MPH, shares pearls from the ADvocate1 and 2 trials examining the use of lebrikizumab for AD.

Jonathan Silverberg, MD, PhD, MPH, talks about therapies used for AD, including nemolizumab.

LEO Pharma reveals promising phase 2b trial results for temtokibart, a treatment targeting moderate to severe atopic dermatitis effectively.

Explore the significant mental health and socioeconomic impacts of atopic dermatitis and alopecia areata, revealing urgent needs for better support and awareness.

Tralokinumab offers a promising alternative for patients with atopic dermatitis experiencing dupilumab-related arthralgia, achieving skin clearance and symptom relief.

Triveni Bio initiates a phase 1 trial for TRIV-509, a promising treatment for atopic dermatitis, targeting key inflammatory pathways.

Albert Chiou, MD, MBA, discusses early clinical data on soquelitinib for atopic dermatitis, highlighting its targeted ITK inhibition, dose-dependent efficacy, favorable safety profile, and more.

The study offers reassurance regarding the safety profile of JAKis in patients with severe atopic dermatitis, particularly concerning their impact on venous thromboembolic events.

Christopher Bunick, MD, PhD, discusses key differences in AD biologics and challenges in achieving optimal treatment targets.

GLP-1 receptor agonists show promise in reducing cardiovascular risks for patients with chronic inflammatory skin diseases like psoriasis and atopic dermatitis.

Extended oral corticosteroid therapy in patients with atopic dermatitis significantly increases cardiovascular and thrombotic risks, urging careful treatment evaluations.

Researchers reveal TRIV-509, a novel monoclonal antibody, shows promise in rapidly improving atopic dermatitis by restoring skin barrier integrity and reducing inflammation.